Not exact matches
A well written business plan stating the nature of the business,
funds required, budget allocation,
future projections and profitability should be accompanied with the loan
application.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and
future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of
funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug
applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's
future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
If you are interested in submitting a grant
application for Rising Together
funds, we will provide more information on the
application process in the near
future.
Because of uncertainty about the
future, research leaders say, UK institutions that rely on EU
funding are already seeing their staff dropped or demoted from planned collaborative EU grant
applications, and top talent could already be leaving Britain.
For example, we will be able to collaborate with researchers that work on integration of active and passive devices in silicon for telecommunication («Silicon Photonics for
Future Systems» EPSRC program grant) or sensing
applications («Mid-IR silicon photonics sources, detectors and sensors»
funded by the Royal Society) and that will certainly facilitate progress achieved in MIGRATION.»
The
application of these findings goes far beyond decision - making that will affect those currently studying, and has an important role to play in enabling universities to attract students, and the fees and
funding that they bring, in the
future.
Find ways to bridge the divide between charters and district schools, including
future convenings, charter - district collaborative efforts
funded through a pilot program, and improved
application, authorizing, and oversight practices.
In opening the
application period for the Career Pathways Trust grants, state leaders made it clear that they'll be looking for proposals that show schools and their private - sector partners can
fund their own programs in the near -
future.
She was the kind of girl who could do uncool things like act as secretary for the
Future Farmers of America after - school club or solicit
funds for Unicef during lunch hour (she told me having a wide range of interests looked good on college
applications) and the consensus would still be: Wow.
At the outset, PACE
funding will be available only for solar energy installations, though in the
future other renewable energy and energy efficient
applications may become eligible.
Making an exceptional case
funding application in itself is complex requiring a very detailed analysis of the case history and need for
future funding, on top of the standard assessment of the means and merits of a client's case.
Although not binding on
future courts because this was an ex parte
application, this is a helpful development in the expansion of
funding in Cayman outside the insolvency context.
R (on the
application of Luton Borough Council & Others) v Secretary of State for Education [2011] EWHC 217 (Admin) Judicial review of the Secretary of State's decision to withdraw
funding for the «Building Schools for the
Future» programme
R (on the
application of Luton Borough Council & Others) v Secretary of State for Education [2011] EWHC 217 (Admin) Judicial review of the Secretary of State's decision to withdraw
funding for the «Building Schools for the
Future» programme, with Peter Oldham QC
New vehicles have spanned the gamut: actively managed crypto asset hedge
funds,
futures, single coin investment trusts, passive index
funds,
funds of
funds and dozens of
applications for exchange - traded products.
In the
future, using emergent network assets (including non-fungible assets such as namespaces) as a
funding mechanism may become the dominant business model for decentralized
applications.
That
application was also rejected by SEC on the ground that Bitcoin
futures were not available at the time when VanEck was planning to operate their
funding program.
Therefore, we who believe in the
future of blockchain technology, strive to help Japan stay competitive and contribute to the evolution of blockchain technology by sharing information, competing fairly, promoting blockchain, actively expanding the scope of blockchain
applications, and supporting
funding for blockchain research.
Back in October, two firms who had applied to launch these kinds of
funds — Intercontinental Exchange and Van Eck Associates — withdrew their ETF
applications after the United States» Securities and Exchange Commission (SEC) determined these
funds shouldn't go live until after Bitcoin
futures officially materialized.
ProShares and VanEcks
applications for bitcoin exchange - traded
funds have apparently stalled because the bitcoin
futures they wanted to track do nt...
This is not the first time that
fund providers have withdrawn bitcoin ETF
applications under SEC pressure, but many analysts predicted that the launch of bitcoin
futures would quickly lead to regulatory approval for these products.
Led the design of a major release that enabled the
application to calculate highly accurate
future projections of mutual
fund expense accruals using multiple parameters.
As a result of these changes a number of group recipients were advised that pursuant to s. 183 NTA their
funding will be terminated unless they are directly involved as a party or
future party in proceedings relating to particular native title
applications.